Skip to content
OpenCapital
Get started

Mirum Pharmaceuticals, Inc. MIRM Accrued clinical trials

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp
FCF margin-30.3%—

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Reported directly by Mirum Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept mirm:AccruedClinicalTrialsCurrent.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s accrued clinical trials.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s accrued clinical trials?
Mirum Pharmaceuticals, Inc. (MIRM) reported accrued clinical trials of $25.69M in Q1 2026.
How has Mirum Pharmaceuticals, Inc.'s accrued clinical trials changed year-over-year?
Mirum Pharmaceuticals, Inc.'s accrued clinical trials increased by 161.0% year-over-year, from $9.84M to $25.69M.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s accrued clinical trials?
Over 2 years (2023 to 2025), Mirum Pharmaceuticals, Inc.'s accrued clinical trials has grown at a 38.6% compound annual growth rate (CAGR), from $7.27M to $13.96M.